Activation of Nuclear Factor-kappa B signalling promotes cellular senescence

Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
Oncogene (Impact Factor: 8.56). 01/2011; 30(20):2356-66. DOI: 10.1038/onc.2010.611
Source: PubMed

ABSTRACT Cellular senescence is a programme of irreversible cell cycle arrest that normal cells undergo in response to progressive shortening of telomeres, changes in telomeric structure, oncogene activation or oxidative stress. The underlying signalling pathways, of major clinicopathological relevance, are unknown. We combined genome-wide expression profiling with genetic complementation to identify genes that are differentially expressed when conditionally immortalised human fibroblasts undergo senescence upon activation of the p16-pRB and p53-p21 tumour suppressor pathways. This identified 816 up and 961 downregulated genes whose expression was reversed when senescence was bypassed. Overlay of this data set with the meta-signatures of genes upregulated in cancer showed that nearly 50% of them were downregulated upon senescence showing that even though overcoming senescence may only be one of the events required for malignant transformation, nearly half of the genes upregulated in cancer are related to it. Moreover 65 of the up and 26 of the downregulated genes are known downstream targets of nuclear factor (NF)-κB suggesting that senescence was associated with activation of the NF-κB pathway. Direct perturbation of this pathway bypasses growth arrest indicating that activation of NF-κB signalling has a causal role in promoting senescence.

Download full-text


Available from: Parmjit S Jat, Mar 18, 2014
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: NF-kappa B is considered a major contributor to tumor development, but how this factor functions in the initial stages of oncogenesis is not clear. In a model of Ras-induced transformation, we probed NF-kappa B function as preneoplastic cells formed tumors in mice. As previously shown, the p65 subunit of NF-kappa B acts as a tumor suppressor in normal cells by sustaining senescence following DNA damage. Our current data reveal that, following immortalization, p65 switches to an oncogene by counteracting the surveillance properties of immune cells. NF-kappa B exerts this effect by protecting transformed cells against macrophage-derived proapoptotic factors, tumor necrosis factor, and nitric oxide. Additionally, NF-kappa B acts through transforming growth factor beta (TGF-beta) to mitigate T cell cytotoxicity and other factors to expand myeloid-derived suppressor cells. Together, these data suggest that NF-kappa B functions in the early stages of transformation by suppressing immune surveillance of both innate and adaptive immune cells, information that may be useful for targeted immunotherapies.
    Cell Reports 10/2014; 9(1). DOI:10.1016/j.celrep.2014.08.049 · 7.21 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cellular senescence is a stable cell cycle arrest, caused by insults, such as: telomere erosion, oncogene activation, irradiation, DNA damage, oxidative stress, and viral infection. Extrinsic stimuli such as cell culture stress can also trigger this growth arrest. Senescence is thought to have evolved as an example of antagonistic pleiotropy, as it acts as a tumor suppressor mechanism during the reproductive age, but can promote organismal aging by disrupting tissue renewal, repair, and regeneration later in life. The mechanisms underlying the senescence growth arrest are broadly considered to involve p16INK4A-pRB and p53-p21CIP1/WAF1/SDI1 tumor suppressor pathways; but it is not known what makes the senescence arrest stable and what the critical downstream targets are, as they are likely to be key to the establishment and maintenance of the senescent state. MYB-related protein B (B-MYB/MYBL2), a member of the myeloblastosis family of transcription factors, has recently emerged as a potential candidate for regulating entry into senescence. Here, we review the evidence which indicates that loss of B-MYB expression has an important role in causing senescence growth arrest. We discuss how B-MYB acts, as the gatekeeper, to coordinate transit through the cell cycle, in conjunction with the multivulval class B (MuvB) complex and FOXM1 transcription factors. We also evaluate the evidence connecting B-MYB to the mTOR nutrient signaling pathway and suggest that inhibition of this pathway leading to an extension of healthspan may involve activation of B-MYB.
    Aging cell 06/2014; 13(5). DOI:10.1111/acel.12242 · 5.94 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: FoxM1 is a member of the forkhead family of transcription factors. Since its identification 15 year ago, numerous studies have progressively contributed to our current understanding on FoxM1 functions. Early work showed that FoxM1 regulates the transcriptional program of the G2 phase of the cell cycle, and is essential for proper mitotic progression and genomic stability. Moreover, FoxM1 was found to be overexpressed in many different types of human cancer, suggesting a role of FoxM1 in tumor proliferation. In the past years, a significant number of studies have formally demonstrated the involvement of FoxM1 in different aspects of tumorogenesis, including angiogenesis, invasion, and metastasis. In addition to this, recent studies have placed FoxM1 in DNA damage response and senescence pathways, two pathways relevant to tumor progression and the response to cancer therapies. Here, we review and discuss the molecular mechanisms through which FoxM1 executes these new roles, and the implications for the potential use of FoxM1 as a therapeutic target in cancer.
    Frontiers in Oncology 03/2013; 3:30. DOI:10.3389/fonc.2013.00030